FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2280-2282 May 22, 2008 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Stone, G. W. PubMed Citation

The goals of the initial management of ST-segment elevation myocardial infarction include swift restoration of flow within the occluded coronary artery, prevention of early reinfarction, and avoidance of complications of reperfusion therapy.^1,2 The selection of the reperfusion strategy, either the preferred percutaneous coronary intervention (PCI) or fibrinolysis, is usually driven by institutional access to primary PCI. Thus, the decision that clinicians most commonly grapple with at the time of the patient's presentation is the selection of adjunctive anticoagulant and antiplatelet therapy. In this issue of the Journal, Stone and colleagues report on a large, randomized trial that tested an anticoagulant . . . [Full Text of this Article]

Source Information

From the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston.

This article has been cited by other articles:

• (2008). Bivalirudin During PCI in Patients with Acute MI. JWatch Emergency Med. 2008: 1-1 [Full Text]  
• (2008). Bivalirudin Alone During Primary Percutaneous Coronary Intervention?. Journal Watch Cardiology 2008: 2-2 [Full Text]